A 52-year-old man with chronic pancreatitis and pancreatic exocrine insufficiency developed a duodenal bulb stenosis that caused postprandial vomiting. He underwent a gastroenteric anastomosis to restore the intestinal flow. He was readmitted 30 days after discharge with hematemesis, hypovolemic shock, and severe anemia (hemoglobin 6.6g/dL). He was resuscitated, and an emergency gastroscopy was carried out, which showed an oozing bleeding point likely secondary to a post-surgical vascular ectasia in the border of the gastroenteric anastomosis (Fig. 1 a, b).

Initially the bleeding site was treated with local submucosal injection of fibrin glue (Beriplast P Combi-Set; CSL Behring GmbH, Marburg, Germany) to create a large cushion to jam the vessel, but bleeding restarted at an increased rate (Video 1). We attempted to inject a solution of saline and epinephrine, without success (Fig. 1 c). The increased blood flow and clots obscured the bleeding site, rendering it difficult to perform any further conventional treatment that required accurate localization of the bleeding source (Fig. 1 d).

We decided to use Hemospray (Cook Medical, Winston Salem, North Carolina, USA). A 10-Fr catheter was advanced approximately 2 cm out of the scope and was placed approximately 2 cm from the bleeding site. Multiple consecutive bursts created a hemostatic powder barrier, which successfully stopped the bleed (Fig. 2; Video 1). There were no adverse events and no late recurrent bleeding.

Current hemostatic techniques include injection therapy (epinephrine, sclerosants, or fibrin glue), thermal therapy (heater probe, bipolar cautery, or argon plasma coagulation), and mechanical therapy (standard metal clips, over-the-scope clips, or band ligation). However, these techniques do have some limitations, especially in the case of massive bleeding that obscures the endoscopic view. One possible major advantage of the hemostatic powder over the current endoscopic modalities may be its ability to control bleeding from obscured bleeding sites. The advent of Hemospray potentially obviates the need for en face therapeutic positioning.

Competing interests: None